LEADER 01914nam  2200373   450 
001 9910688497603321
005 20230628215313.0
024 7 $a10.5772/intechopen.83074
035   $a(CKB)5400000000045435
035   $a(NjHacI)995400000000045435
035   $a(EXLCZ)995400000000045435
100   $a20230628d2020      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aBiological Therapy for Inflammatory Bowel Disease /$fRaquel Franco Leal, Tristan Torriani, editors
210  1$aLondon :$cIntechOpen,$d2020.
215   $a1 online resource (140 pages)
311   $a1-78985-954-9 
320   $aIncludes bibliographical references.
330   $aThe treatment of inflammatory bowel disease (IBD) has posed a major challenge since its appearance. Biomedical researchers, physicians, gastroenterologists, and surgeons have struggled to improve the quality of life of their patients and have sought, above all else, to keep the disease under remission for as long as possible. Blockers for tumoral necrosis factor alpha (TNF-?) were the first biological drugs to be discovered and for this reason they played a crucial role in the subsequent evolution of IBD treatment. The aim of this book is to provide an overview of such drugs and the latest developments in IBD immunopathology. Our contributors discuss the main indications, efficacy, and possible side effects of the different types of drugs available today for IBD treatment.
606   $aInflammatory bowel diseases
615  0$aInflammatory bowel diseases.
676   $a616.344
702   $aTorriani$b Tristan
702   $aLeal$b Raquel Franco
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688497603321
996   $aBiological Therapy for Inflammatory Bowel Disease$92263313
997   $aUNINA